Table 1.

Demographic and clinical variables of the study’s sample

	Included patients						Excluded patients
	Olanzapine group		Antipsychotic free		Statisticsd				Statisticse
Variables	Mean	SD	Mean	SD	t	p	Mean	SD	t	p
Age (years)	39.5	10.8	41.4	10.2	−1.3	0.181	44.2	10.8	−1.73	0.085
Patient's education (years)	12.3	1.9	12.1	2.3	0.7	0.456	12.5	2.0	−0.59	0.553
PANSS positive score	18.6	6.2	19.1	5.6	−0.7	0.507	16.2	5.1	1.78	0.076
PANSS negative score	20.4	6.1	19.0	6.1	1.6	0.106	20.5	6.2	−0.52	0.605
Total cholesterol (mg/dl)a	209.1	69.9	203.2	51.0	0.7	0.482	204.4	54.5	0.15	0.884
HDL cholesterol (mg/dl)b	39.8	13.3	44.9	15.6	−2.5	0.012	45.3	12.9	−1.00	0.320
HbA1C (%)c	5.8	1.5	5.9	1.6	−0.5	0.606	5.9	1.8	0.02	0.987
Blood pressure (systolic, mmHg)	124.4	15.3	126.1	17.9	−0.7	0.459	122.0	14.9	0.81	0.419
Blood pressure (diastolic, mmHg)	79.5	10.6	80.0	11.4	−0.3	0.784	76.4	8.2	1.29	0.198
Body mass index	29.9	6.4	29.2	6.7	0.9	0.393	28.6	6.5	0.61	0.542
Log10leptin	1.93	0.33	1.88	0.40	1.09	0.278	1.88	0.30	0.35	0.728
Neurocognitive test score
Verbal memory	0.03	0.96	0.01	1.05	0.14	0.886
Vigilance	0.07	0.97	0.11	1.11	−0.24	0.812
Processing speed	0.19	0.98	0.19	1.14	−0.02	0.986
Reasoning	0.19	0.93	0.01	1.01	1.41	0.161
Working memory	0.02	0.98	−0.03	1.00	0.37	0.709
Days between blood collection and clinical evaluation	10.9	8.4	12.1	10.7	0.86	0.389

	N	%	N	%	X2	p	N	%	X2	p
Gender (Male)	93	82	80	78	0.88	0.434	15	60	5.53	0.036
Race (White)	78	69	44	43	10.63	0.001	15	60	0.10	0.833
Donated blood at fasting state	59	55	42	43	3.18	0.089	12	48	0.20	1.000
Total N	113		102				25

^aUnavailable from 2 subjects

^bUnavailable from 3 subjects

^cUnavaiable from 42 subjects

^dolanzapine group vs. antipsychotic-free group

^eincluded vs. excluded